Exemestane is effective for the chemoprevention of breast cancer

Abstract

The author discusses a study conducted by Paul Goss, a Harvard Medical School professor and a director at the Massachusetts General Hospital in Boston, which looks into the role of aromatase inhibitor exemestane in breast cancer treatment in postmenopausal women. He asserts that the study discovers a 65% reduction in invasive breast cancer incidence with exemestane versus placebo. He also claims that Goss suggests that exemestane is more safe than other chemoprevention options.